——ETF市场周报2025.05.23 李倩云 证券分析师执业证书编号：S0740520050001 邮 箱：liqy02@zts.com 汤伟杰 中 泰 证 券 研 究 所 专 业 ｜ 领 先 ｜ 深 度 ｜ 诚 信 ｜ 证 券 研 究 报 告 ｜ 科技及高制板块交易最热， 科技及高制板块资金流入最多 证券分析师执业证书编号：S0740523050001 邮 箱：xiongjy01@zts.com 熊婧妍 证券分析师执业证书编号：S0740523110005 邮 箱：xiongjy01@zts.com 2 0 2 5 . 0 5 . 2 4 1 投资要点 风险提示：历史数据不代表未来；政策及经济超预期波动；流动性冲击影响市场，研报信息更新不及时的风险。 2 n ETF市场规模：当前市场上共有1178只ETF，总规模为41087.35亿元。股票型ETF数量最多，为 948只，规模为29638.73亿元，占市场规模的72.14%，其次是跨境ETF。股票型ETF中，主题指数 ETF数量最多，为448只，规模为4560.88亿元，其次为规模指数ETF。 n 权益ETF估值：A股市场上，ETF跟踪规模最高的30个指数 ...

Investment Rating - The report indicates a bullish probability of 62% for the coal industry and 61% for the media industry [4]. Core Insights - The report highlights significant inflows in the food and beverage, as well as mechanical equipment sectors [5]. - The active equity funds have increased their positions notably in the beauty and personal care sector [5]. - The ETF share growth is particularly high in the military industry, while the automotive sector has seen a decrease in share [4]. Summary by Relevant Sections Industry Investment Rating - The coal industry has a bullish probability of 62% and the media industry has a probability of 61% [4]. Fund Flow Insights - The food and beverage sector ranks first in net inflows, while mechanical equipment ranks second [4]. - Active equity funds have increased their positions in the beauty and personal care sector, indicating a positive outlook [5]. ETF Insights - The report identifies ETFs with high growth potential based on the AI model scoring above 0.8, focusing on those with a recent average daily trading volume exceeding 30 million [7]. - Specific ETFs highlighted include the Hong Kong Dividend Low Volatility ETF and the Hong Kong Medical ETF [8].

全国首单中小微企业支持可续期公募公司债券在北交所发行,引 导金融资源流向中小微企业 北交所点评报告 证券研究报告/行业点评报告 2025年05月23日 北交所 增持(维持) 呼级· 报告摘要 全国首单中小微企业支持可续期公募公司债券在北交所成功发行 1）2025年4月23日,江西省金融控股集团有限公司在北交所公开发行全国首单中 小微企业支持可续期公司债券。本期债券发行规模5亿元,期限 3+N 年,发行利率 2.50%。 2 )本期债券募集资金中 3.5 亿元用于支持产业链上下游或自身经营业务相关的中小微 企业发展,1.5 亿元用于补充流动资金。本期发行通过为集团产业链上下游相关中小 微企业提供流动性支持的方式,贯彻普惠金融导向,破解中小微企业"融资难、融资产" 问题。 Email: fengsheng@zts.com.cn 分析师:杨帅 执业证书编号:S0740524040002 Email: yangshuai01@zts.com.cn 基本状况 | 上市公司数 | 265 | | --- | --- | | 行业总市值(亿元) | 7,962.42 | | 行业流通市值(亿元) | 4,745.49 | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9] Core Views - The company has signed a licensing agreement with Pfizer for the PD1×VEGF dual antibody SSGJ707, receiving an upfront payment of $1.25 billion, which is the largest for a Chinese innovative drug license-out, along with potential milestone payments of $4.8 billion and double-digit royalties on net sales [4][6] - The company is expected to achieve revenue growth of 12% to 14% from 2025 to 2027, with projected revenues of 102.01 billion, 114.94 billion, and 131.53 billion yuan respectively [6] - The net profit forecast for the same period is 23.45 billion, 26.48 billion, and 30.27 billion yuan, reflecting a growth rate of 12.2% to 14.3% [6] Summary by Sections Financial Performance - The company is projected to have operating revenues of 7,836 million yuan in 2023, increasing to 10,201 million yuan in 2025, with a year-on-year growth rate of 14% in 2023 and 12% in 2025 [2] - The net profit attributable to the parent company is expected to rise from 1,549 million yuan in 2023 to 2,345 million yuan in 2025, with a significant increase of 35% in 2024 [2] - Earnings per share (EPS) is forecasted to grow from 0.65 yuan in 2023 to 0.98 yuan in 2025 [2] Market Position and Prospects - The PD1×VEGF dual antibody market is expected to grow significantly, with SSGJ707 showing promising clinical data and a strong partnership with Pfizer, which enhances the clinical development speed in the U.S. [6] - The company has a robust pipeline with four mid-to-late stage monoclonal antibodies, including IL17, which is expected to be commercialized in 2025, indicating a strong potential for revenue generation [6] Valuation Metrics - The price-to-earnings (P/E) ratio is projected to decrease from 28.5 in 2023 to 18.9 in 2025, indicating an improving valuation as earnings grow [2] - The price-to-book (P/B) ratio is expected to decline from 3.2 in 2023 to 2.4 in 2025, reflecting a more attractive valuation over time [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][9] Core Views - The company has signed a licensing agreement with Pfizer for the PD1×VEGF dual antibody SSGJ707, receiving an upfront payment of $1.25 billion, which is the largest for a Chinese innovative drug license-out, along with potential milestone payments of $4.8 billion and double-digit royalties on net sales [4][6] - The company is expected to achieve revenue growth of 12% to 14% from 2025 to 2027, with projected revenues of 102.01 billion, 114.94 billion, and 131.53 billion yuan respectively [6] - The company is anticipated to see a significant acceleration in domestic revenue due to multiple late-stage clinical assets, including IL17 monoclonal antibody expected to commercialize in 2025 [6] Summary by Sections Financial Forecasts - Projected operating revenue (in million yuan): 7,836 (2023A), 9,108 (2024A), 10,201 (2025E), 11,494 (2026E), 13,153 (2027E) with growth rates of 14%, 16%, 12%, 13%, and 14% respectively [2] - Expected net profit attributable to shareholders (in million yuan): 1,549 (2023A), 2,090 (2024A), 2,345 (2025E), 2,648 (2026E), 3,027 (2027E) with growth rates of -19%, 35%, 12%, 13%, and 14% respectively [2] - Earnings per share (in yuan): 0.65 (2023A), 0.87 (2024A), 0.98 (2025E), 1.10 (2026E), 1.26 (2027E) [2] Market Position and Development - The PD1×VEGF dual antibody market is validated, with significant clinical results from competitors enhancing the outlook for SSGJ707 [6] - The company’s collaboration with Pfizer is expected to accelerate clinical development in the U.S. due to Pfizer's robust clinical and commercialization capabilities [6] Valuation Metrics - Projected P/E ratios: 28.5 (2023A), 21.2 (2024A), 18.9 (2025E), 16.7 (2026E), 14.6 (2027E) [2] - Projected P/B ratios: 3.2 (2023A), 2.9 (2024A), 2.4 (2025E), 2.0 (2026E), 1.7 (2027E) [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][8] Core Views - The company has strong revenue growth and is on the verge of breakthroughs in its clinical pipeline [4][5] - The recent licensing agreement with Pfizer for the PD1×VEGF dual antibody SSGJ707 is a significant milestone, with an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, along with double-digit royalties on net sales [4][5] - The company is expected to achieve substantial revenue growth from its main business, with key products in late-stage clinical development [5] Financial Summary - Projected revenue for 2023A is 1,014 million, with a growth rate of 23% year-over-year; expected revenue for 2025E is 1,370 million, with a growth rate of 15% [3] - Projected net profit for 2023A is 295 million, with a staggering growth rate of 498% year-over-year; expected net profit for 2025E is 300 million, reflecting a decline of 57% [3] - Earnings per share (EPS) is projected to be 0.48 for 2023A and 0.49 for 2025E [3] Clinical Pipeline and Market Potential - The company has four mid-to-late stage clinical assets, each expected to generate over 1 billion in revenue, with the IL17 monoclonal antibody anticipated to be commercialized in 2025 [5] - The IL1β monoclonal antibody is expected to submit its NDA in 2025, targeting a large patient population with limited treatment options [5] Valuation Metrics - The company is projected to have a P/E ratio of 116.5 for 2025E and a P/B ratio of 6.1 for the same year [3] - The net asset return rate (ROE) is expected to be 5% for 2025E, with a net profit margin of 21.5% [7]

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [4][24]. Core Insights - The company reported a revenue of approximately RMB 86.4 billion for 2024, representing a year-on-year growth of 7.7%. However, the net profit attributable to shareholders was RMB 1.04 billion, a significant decline of 67.3% compared to the previous year [5][6][17]. - The decline in net profit is attributed to a decrease in gross margin and increased impairment provisions due to market downturns. The gross margin for 2024 was 10.5%, down 4.8 percentage points from the previous year [6][9]. - Despite the challenges, the company maintained a strong market position, ranking 8th in industry sales, and focused on acquiring high-quality land reserves in core cities [6][17]. Financial Performance Summary - Revenue and Profit Forecast: - 2023A: Revenue of RMB 80.4 billion, net profit of RMB 3.2 billion - 2024A: Revenue of RMB 86.4 billion, net profit of RMB 1.04 billion - 2025E: Revenue of RMB 90.4 billion, net profit of RMB 1.13 billion - 2026E: Revenue of RMB 92.6 billion, net profit of RMB 1.27 billion - 2027E: Revenue of RMB 97.8 billion, net profit of RMB 1.46 billion [4][15][17]. - The company’s cash flow from operating activities for 2024 was RMB 21.84 billion, a year-on-year increase of 155% [14]. Market Position and Strategy - The company’s sales amount for 2024 was RMB 114.54 billion, a decrease of 19.4% year-on-year, with a sales area of 3.92 million square meters, down 11.9% [6][15]. - The company has adopted a precise investment strategy, focusing on first-tier and key second-tier cities, with over 70% of new land reserves located in these areas [6][15]. - The company’s total land reserves as of the end of 2024 stood at 19.71 million square meters, with 96% located in first and second-tier cities [6][15]. Valuation Metrics - The current Price-to-Earnings (P/E) ratio is projected to be 14.8 for 2025, decreasing to 11.4 by 2027. The Price-to-Book (P/B) ratio is currently at 0.30, which is below the average of comparable companies [4][17][18].

gzitiao 立足线缆深耕军工，业绩有望持续改善 电网设备 执业证书编号：S0740521080001 Email：chendr01@zts.com.cn 执业证书编号：S0740522020001 Email：zengbiao@zts.com.cn 分析师：马梦泽 执业证书编号：S0740523060003 Email：mamz@zts.com.cn | 总股本(百万股) | 525.74 | | --- | --- | | 流通股本(百万股) | 452.94 | | 市价(元) | 8.39 | | 市值(百万元) | 4,410.95 | | 流通市值(百万元) | 3,800.13 | 相关报告 通达股份（002560.SZ） 证券研究报告/公司点评报告 2025 年 05 月 20 日 | 评级： | 增持（首次） | 公司盈利预测及估值 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | | 2023A | 2024A | 2025E | 2026E | 2027E | | 分析师：陈 ...

证券研究报告 【中泰汽车|何俊艺团队】汽车周报（05/12-05/18） 持续看好强势自主整车，年度重视整车&智驾&机器人 | 汽车行业首席分析师：何俊艺 | 汽车行业分析师：刘欣畅 | 汽车行业分析师：毛䶮玄 | | --- | --- | --- | | S0740523020004 | S0740522120003 | S0740523020003 | | hjy@zts.com.cn | liuxc03@zts.com.cn | maoyx@zts.com.cn | | 汽车行业分析师：汪越 | 汽车行业分析师：白臻哲 | | | S0740525010002 | S0740524070006 | | | wangyue07@zts.com.cn | baizz@zts.com.cn | | 2025年5月21日 1 目 录 一、核心观点：持续看好强势自主整车，年度重视整车&智驾&机器人 二、行情跟踪：全行业&汽车板块&覆盖标的跟踪 三、行业景气度：终端&订单&出口总量+分车企数据跟踪 四、重要新闻 五、个股跟踪 六、风险提示 2 核心观点：持续看好强势自主整车，年度重视整车&智驾&机器人 3 ◼ 周 ...

北交所进一步支持发行科技创新债券，服务新质生产力 ——北交所点评报告 分析师：冯胜 执业证书编号：S0740519050004 Email：fengsheng@zts.com.cn 分析师：杨帅 执业证书编号：S0740524040002 Email：yangshuai01@zts.com.cn | | | | 上市公司数 | 265 | | --- | --- | | 行业总市值(亿元) | 8,414.15 | | 行业流通市值(亿元) | 5,018.26 | 1、《北交所修订募集资金指引和重组 相关规则，强化监管与激发市场活力 并举》2025-05-20 2、《北交所交易热度上涨，募集资金 管理新规即将实施》2025-05-18 3、《北交所存量股票 920 代码上线， 独 立 代 码 增 强 市 场 辨 识 度 》 2025-05-16 北交所 证券研究报告/行业点评报告 2025 年 05 月 22 日 评级： 增持（维持） 报告摘要 中国人民银行、中国证监会联合发布通知，支持发行科技创新债券 1）党的二十届三中全会明确提出，要加快多层次债券市场建设，构建同科技创新相 适应的科技金融体制。近日，中 ...